SCHEMBL31727865

SCHEMBL31727865

Cc1ccc(S(=O)(=O)N=[S@@](C)(=O)c2ccc(CBr)cc2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ F2 P00734 2/20 0.41
▸ PRSS1 P07477 2/20 0.41
▸ PRSS2 P07478 2/20 0.41
▸ PRSS3 P35030 2/20 0.41
▸ ALDH1A1 P00352 4/20 0.40
▸ SMN1; SMN2 Q16637 3/20 0.40
▸ RECQL P46063 1/20 0.40
▸ GAA P10253 2/20 0.39
▸ LMNA P02545 2/20 0.39
▸ CYP2C19 P33261 2/20 0.39
▸ HTT P42858 1/20 0.39
▸ MEN1 O00255 2/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ CYP2C9 P11712 2/20 0.38
▸ CYP1A2 P05177 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.37
▸ CYP3A4 P08684 1/20 0.37
▸ HPGD P15428 1/20 0.36
▸ CA12 O43570 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20323486 0.84 F2 (0.41) F2PRSS1PRSS2PRSS3ALDH1A1
SCHEMBL31726654 0.84 SMN1; SMN2 (0.46) F2PRSS1PRSS2PRSS3ALDH1A1
SCHEMBL17137206 0.80 KMT2A (0.51) F2PRSS1PRSS2PRSS3ALDH1A1
SCHEMBL8885093 0.77 GAA (0.67) ALDH1A1SMN1; SMN2GAACYP2C19HTT
SCHEMBL10480884 0.74 GAA (0.45) ALDH1A1SMN1; SMN2GAALMNACYP2C19
SCHEMBL31727039 0.74 CA1 (0.36) F2PRSS1PRSS2PRSS3ALDH1A1
SCHEMBL13784508 0.73 CES2 (0.41) ALDH1A1SMN1; SMN2RECQLKMT2APOLB
SCHEMBL9738285 0.73 F2 (0.53) F2PRSS1PRSS2PRSS3ALDH1A1
SCHEMBL135563 0.73 F2 (0.53) F2PRSS1PRSS2PRSS3ALDH1A1
SCHEMBL121442 0.72 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025233865-A1 ENPP1 INHIBITORS RE VENTURES I, LLC (US) 2025-11-13 — — WO disclosed
Send feedback